Thursday, June 13, 2024

HomeStock MarketActuate Therapeutics, oncology drug developer, sets terms for $50M IPO (Pending:ACTU)

Actuate Therapeutics, oncology drug developer, sets terms for $50M IPO (Pending:ACTU)

IPO and stock growth graph

mapo

Oncology drug developer Actuate Therapeutics (ACTU) has set terms for a proposed $50M initial public offering.

Actuate said in an SEC filing that it was looking to offer 5.6M shares priced between $8 and $10, which would raise around $50M if priced at the


Source link

Bookmark (0)
ClosePlease login
RELATED ARTICLES
- Advertisment -spot_img

Most Popular

Sponsored Business

- Advertisment -spot_img